[{"id":"78ef7659-8d3d-4df9-b4a9-a9556d985a98","acronym":"","url":"https://clinicaltrials.gov/study/NCT05159518","created_at":"2021-12-16T14:54:02.338Z","updated_at":"2024-07-02T16:35:26.597Z","phase":"Phase 1","brief_title":"A Study of PRT2527 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05159518","lead_sponsor":"Prelude Therapeutics","biomarkers":" HER-2 • MYC","pipe":" | ","alterations":" HR positive • HER-2 negative • MYC amplification","tags":["HER-2 • MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • MYC amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRT2527"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/14/2022","start_date":" 02/14/2022","primary_txt":" Primary completion: 12/06/2023","primary_completion_date":" 12/06/2023","study_txt":" Completion: 12/06/2023","study_completion_date":" 12/06/2023","last_update_posted":"2023-12-11"},{"id":"c9c366ea-e303-45e9-adda-89fe67d98af6","acronym":"VNC-152-101","url":"https://clinicaltrials.gov/study/NCT02635672","created_at":"2021-05-18T17:53:54.105Z","updated_at":"2024-07-02T16:35:39.904Z","phase":"Phase 1","brief_title":"Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer","source_id_and_acronym":"NCT02635672 - VNC-152-101","lead_sponsor":"Vincerx Pharma, Inc.","biomarkers":" MYC","pipe":" | ","alterations":" MYC amplification • MYC expression","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC amplification • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • enitociclib (VIP152)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/10/2016","start_date":" 02/10/2016","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-08-16"},{"id":"12b373a9-f27e-4aa8-b2c5-2cb259826f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03718091","created_at":"2021-01-18T18:13:18.198Z","updated_at":"2024-07-02T16:35:43.598Z","phase":"Phase 2","brief_title":"M6620 (VX-970) in Selected Solid Tumors","source_id_and_acronym":"NCT03718091","lead_sponsor":"Massachusetts General Hospital","biomarkers":" BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation","tags":["BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • CHEK2 • FANCA • RAD51B • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CCNE1 amplification • CDK12 mutation • ATRX mutation • CHEK2 mutation • FBXW7 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e berzosertib (M6620)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 06/01/2020","primary_completion_date":" 06/01/2020","study_txt":" Completion: 07/08/2020","study_completion_date":" 07/08/2020","last_update_posted":"2023-07-07"},{"id":"b2d3e38f-bf00-4920-aff3-f61daeca6754","acronym":"","url":"https://clinicaltrials.gov/study/NCT02873975","created_at":"2021-01-18T14:06:40.199Z","updated_at":"2024-07-02T16:36:02.020Z","phase":"Phase 2","brief_title":"A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency","source_id_and_acronym":"NCT02873975","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • ATM mutation • MYC amplification • PALB2 mutation • CCNE1 amplification • FBXW7 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation","tags":["BRCA1 • BRCA2 • MYC • CCNE1 • FBXW7 • CHEK2 • RAD51C • RAD51D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • ATM mutation • MYC amplification • PALB2 mutation • CCNE1 amplification • FBXW7 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prexasertib (ACR-368)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 10/12/2016","start_date":" 10/12/2016","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 07/01/2021","study_completion_date":" 07/01/2021","last_update_posted":"2022-10-21"},{"id":"d0cc18fc-dcf3-4b22-ba8d-fbfde5473a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT02884453","created_at":"2021-01-18T14:09:32.527Z","updated_at":"2024-07-02T16:36:55.626Z","phase":"Phase 2","brief_title":"Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma","source_id_and_acronym":"NCT02884453","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • MYC","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • MYC amplification • MYC amplification + HER-2 amplification","tags":["HER-2 • MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • MYC amplification • MYC amplification + HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 17","initiation":"Initiation: 07/19/2016","start_date":" 07/19/2016","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2019-09-18"},{"id":"274b6789-cafa-442a-b349-5cb43132ed40","acronym":"","url":"https://clinicaltrials.gov/study/NCT02656849","created_at":"2021-01-18T12:56:12.287Z","updated_at":"2025-02-25T17:23:00.771Z","phase":"Phase 2","brief_title":"BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors","source_id_and_acronym":"NCT02656849","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • CCNE1 • MCL1","pipe":" | ","alterations":" MYC amplification • CCNE1 amplification • MCL1 amplification","tags":["MYC • CCNE1 • MCL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC amplification • CCNE1 amplification • MCL1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e roniciclib (BAY1000394)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2016-07-01"}]